SynthesisMedicine2026
T-cell lymphoblastic lymphoma of the breast: A retrospective observational study and literature review.
Synthesis in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study aims to explore the diagnosis and treatment of T-cell lymphoblastic lymphoma (T-LBL) of the breast. We retrospectively analyzed the clinical data of a patient with breast T-LBL jointly managed by our hospital and Ruijin Hospital, Shanghai. A systematic literature review was conducted across PubMed, Web of Science, Embase, Cochrane Library, China Biomedical Literature Database, China national knowledge infrastructure, Wanfang, and Wipro databases up to May 10, 2024, using Boolean operators (e.g., ("T-cell lymphoblastic lymphoma" OR "T-LBL") AND ("breast" OR "mammary")). Including our case, 11 patients were studied. All were female (mean age 31.81 ± 11.97 years). Five cases involved both breasts, 6 were unilateral. Ten cases had extramammary involvement. Immunohistochemistry was positive for both terminal deoxynucleotidyl transferase and cluster of differentiation (CD3) in 9 breast lesions. Imaging included ultrasound (n = 6), mammography (n = 6), magnetic resonance imaging (n = 2), and positron emission tomography-computed tomography (n = 2). Most patients (n = 10) received chemotherapy, with some supplemented by radiotherapy and intrathecal prophylaxis. Breast T-LBL is exceedingly rare. Accurate diagnosis is crucial for management. Future prospective studies are needed to optimize diagnostic and therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.